Latest news with #Purohit
Business Insider
19-05-2025
- Business
- Business Insider
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Waters (WAT) and Cingulate Inc (CING)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axsome Therapeutics (AXSM – Research Report), Waters (WAT – Research Report) and Cingulate Inc (CING – Research Report). Confident Investing Starts Here: Axsome Therapeutics (AXSM) In a report issued on May 16, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics, with a price target of $190.00. The company's shares closed last Friday at $107.53. According to Purohit 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.5% and a 30.9% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, BioMarin Pharmaceutical, and Arcutis Biotherapeutics. Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $177.85, a 66.6% upside from current levels. In a report issued on May 1, Mizuho Securities also maintained a Buy rating on the stock with a $210.00 price target. Waters (WAT) Bank of America Securities analyst Michael Ryskin reiterated a Hold rating on Waters yesterday and set a price target of $370.00. The company's shares closed last Friday at $359.48. According to Ryskin is a 2-star analyst with an average return of 0.2% and a 45.0% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, West Pharmaceutical Services, and Fortrea Holdings Inc. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Waters with a $393.77 average price target, representing an 11.9% upside. In a report issued on May 6, TD Cowen also maintained a Hold rating on the stock with a $375.00 price target. Cingulate Inc (CING) In a report released yesterday, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Cingulate Inc, with a price target of $11.00. The company's shares closed last Friday at $3.82, close to its 52-week low of $1.80. According to Pachaiyappan has 0 stars on 0-5 stars ranking scale with an average return of -9.8% and a 31.5% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Entrada Therapeutics Inc, and Gain Therapeutics.
Deccan Herald
17-05-2025
- Entertainment
- Deccan Herald
Ali Fazal, Tillotama Shome to feature in 'Beyond'
Directed by Sumit Purohit, the film is set in a ghostly Himalayan town. It is written by Purohit and Saurav Dey, according to the entertainment news outlet Deadline.
India Gazette
16-05-2025
- Science
- India Gazette
ISRO Chairman V. Narayanan Announces Upcoming Weather Surveillance Satellite EOS-09
New Delhi [India], May 16 (ANI): The Indian Space Research Organisation (ISRO) is set to launch its 101st satellite, EOS-09, aboard the Polar Satellite Launch Vehicle (PSLV-C61) on May 18, 2025. According to ISRO Chairman V. Narayanan' The launch is scheduled for 5:59 am from the Satish Dhawan Space Centre in Sriharikota'. The PSLV-C61 rocket was transported to the Mobile Service Tower at the Satish Dhawan Space Centre in Sriharikota for final integration and checks before its scheduled launch on May 18. Former ISRO scientist Purohit also mentioned that EOS-09 would serve as a follow-on to the earlier RISAT-1 mission. This launch is strategically timed,' said former ISRO scientist Manish Purohit. 'It strengthens monitoring at borders and coasts, particularly with respect to sensitive areas. The satellite can detect ingress or suspicious movement deemed vital in anti-terror operations, especially after the recent Pahalgam terror attack and Operation Sindoor,' added Purohit. Earlier ISRO Chairman V. Narayanan stressed the critical role of satellite technology in national security and governance, stating, 'With the PSLV-C61/EOS-09 mission, ISRO continues to demonstrate its commitment to both technological excellence and the national interest.' IN-SPACe Chairman Pawan Kumar Goenka echoed this sentiment, emphasizing the need for constant enhancement of capabilities. ISRO is gearing up to launch the NASA-ISRO Synthetic Aperture Radar (NISAR) satellite on the GSLV-F16 mission. NISAR will utilize dual-band radar technology from both NASA and ISRO to monitor Earth's surface changes, ecosystems, and natural disasters, providing valuable insights into our planet's dynamics. The EOS-09 satellite is a cutting-edge Earth observation satellite designed to bolster India's space-based surveillance capabilities. Fitted with advanced C-band synthetic aperture radar technology, it can capture high-resolution images of the Earth's surface regardless of weather conditions or time of day. This capability enables effective monitoring and management across various sectors (ANI).
Times of Oman
16-05-2025
- Science
- Times of Oman
ISRO Chairman V. Narayanan Announces Upcoming Weather Surveillance Satellite EOS-09
New Delhi: The Indian Space Research Organisation (ISRO) is set to launch its 101st satellite, EOS-09, aboard the Polar Satellite Launch Vehicle (PSLV-C61) on May 18, 2025. According to ISRO Chairman V. Narayanan" The launch is scheduled for 5:59 am from the Satish Dhawan Space Centre in Sriharikota". The PSLV-C61 rocket was transported to the Mobile Service Tower at the Satish Dhawan Space Centre in Sriharikota for final integration and checks before its scheduled launch on May 18. Former ISRO scientist Purohit also mentioned that EOS-09 would serve as a follow-on to the earlier RISAT-1 mission. This launch is strategically timed," said former ISRO scientist Manish Purohit. "It strengthens monitoring at borders and coasts, particularly with respect to sensitive areas. The satellite can detect ingress or suspicious movement deemed vital in anti-terror operations, especially after the recent Pahalgam terror attack and Operation Sindoor," added Purohit. Earlier ISRO Chairman V. Narayanan stressed the critical role of satellite technology in national security and governance, stating, "With the PSLV-C61/EOS-09 mission, ISRO continues to demonstrate its commitment to both technological excellence and the national interest." IN-SPACe Chairman Pawan Kumar Goenka echoed this sentiment, emphasizing the need for constant enhancement of capabilities. ISRO is gearing up to launch the NASA-ISRO Synthetic Aperture Radar (NISAR) satellite on the GSLV-F16 mission. NISAR will utilize dual-band radar technology from both NASA and ISRO to monitor Earth's surface changes, ecosystems, and natural disasters, providing valuable insights into our planet's dynamics. The EOS-09 satellite is a cutting-edge Earth observation satellite designed to bolster India's space-based surveillance capabilities. Fitted with advanced C-band synthetic aperture radar technology, it can capture high-resolution images of the Earth's surface regardless of weather conditions or time of day. This capability enables effective monitoring and management across various sectors.
Business Insider
12-05-2025
- Business
- Business Insider
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report), Iovance Biotherapeutics (IOVA – Research Report) and Alector (ALEC – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Axsome Therapeutics (AXSM) Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of $190.00. The company's shares closed last Friday at $107.76. According to Purohit is a 1-star analyst with an average return of -4.1% and a 37.7% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, BioMarin Pharmaceutical, and Arcutis Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $176.07 average price target, a 61.7% upside from current levels. In a report issued on April 29, RBC Capital also maintained a Buy rating on the stock with a $193.00 price target. Wells Fargo analyst Yanan Zhu maintained a Buy rating on Iovance Biotherapeutics on May 9 and set a price target of $18.00. The company's shares closed last Friday at $1.75. According to Zhu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 26.4% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Crispr Therapeutics AG, and Taysha Gene Therapies. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Iovance Biotherapeutics with a $13.83 average price target, representing a 612.9% upside. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target. Alector (ALEC) BTIG analyst Thomas Shrader maintained a Buy rating on Alector on May 9 and set a price target of $5.00. The company's shares closed last Friday at $1.17. According to Shrader is a 2-star analyst with an average return of 0.2% and a 33.8% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and Arcturus Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alector with a $5.50 average price target, which is a 428.8% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock.
